


Foxy-5 TFA

Cat. No.:	HY-P1416A
Molecular Formula:	C ₂₈ H ₄₃ F ₃ N ₆ O ₁₄ S ₂
Molecular Weight:	808.8
Sequence:	{For}-Met-Asp-Gly-Cys-Glu-Leu
Sequence Shortening:	{For}-MDGCEL
Target:	Wnt
Pathway:	Stem Cell/Wnt
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 20 mg/mL (24.73 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM	1.2364 mL	6.1820 mL	12.3640 mL	
		5 mM	0.2473 mL	1.2364 mL	2.4728 mL	
	10 mM	0.1236 mL	0.6182 mL	1.2364 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS					
	Solubility: 7.14 mg/mL (8.83 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model ^{[1][2][3][4]} .
IC ₅₀ & Target	WNT5A ^[1]
In Vivo	Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model ^[1] . Foxy-5 reduces the number of colonic cancer stem cells in a xenograft mouse model of human colonic cancer ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Patent. US20230130144A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418.
- [2]. Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63.
- [3]. Kelsey R. Prostate cancer: Foxy-5 in prostate cancer model. Nat Rev Urol. 2017 Nov;14(11):638.
- [4]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA